Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220498 | 1.00 | FOLH1 (0.56) | FOLH1SIRT2SIRT1ALDH1A1ALOX15 | |
| SCHEMBL5970693 | 1.00 | FOLH1 (0.56) | FOLH1SIRT2SIRT1ALDH1A1ALOX15 | |
| SCHEMBL7087075 | 0.92 | KYNU (0.59) | SIRT2SIRT1ALDH1A1ALOX15CTSK | |
| SCHEMBL11053442 | 0.92 | KYNU (0.59) | SIRT2SIRT1ALDH1A1ALOX15CTSK | |
| SCHEMBL6849362 | 0.92 | FOLH1 (0.58) | FOLH1SIRT2SIRT1PPARAPPARG | |
| SCHEMBL11893028 | 0.92 | FOLH1 (0.58) | FOLH1SIRT2SIRT1PPARAPPARG | |
| SCHEMBL7373019 | 0.92 | FOLH1 (0.58) | FOLH1SIRT2SIRT1PPARAPPARG | |
| SCHEMBL9351629 | 0.91 | FOLH1 (0.53) | FOLH1SIRT2SIRT1ALDH1A1ALOX15 | |
| SCHEMBL16789581 | 0.91 | SIRT2 (0.64) | FOLH1SIRT2SIRT1ALDH1A1ALOX15 | |
| SCHEMBL20696435 | 0.91 | ALDH1A1 (0.59) | ALDH1A1ALOX15CTSKKYNUCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114980933-B | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-6924307-B2 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0209237-A2 | Vinyl-glycyl-amino-beta-lactam derivatives | BEECHAM GROUP PLC (GB) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | FOLH1 1206/4885SIRT2 2929/4885SIRT1 2103/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | FOLH1 1206/4885SIRT2 2929/4885SIRT1 2103/4885 |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | GABBR1, GABRB1, GABBR2 | FOLH1 677/4885SIRT2 3175/4885SIRT1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.